

# Sergey Gilyarevskiy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6465619/publications.pdf>

Version: 2024-02-01

17  
papers

31  
citations

2148532

4  
h-index

2070828

6  
g-index

19  
all docs

19  
docs citations

19  
times ranked

25  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology. <i>Atherothrombosis</i> , 2022, 12, 8-18.	0.1	0
2	Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 332-341.	0.3	0
3	Modern Approaches to the Interpretation of the Results of Large Randomized Clinical Trials. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 311-319.	0.3	0
4	THE APPLICATION OF COMBINED PREPARATIONS WITH CONSTANT DOSES OF ANTIHYPERTENSIVE DRUGS AS THE INITIAL TACTICS OF TREATMENT AT HIGH BLOOD PRESSURE LEVEL: PROVEN FACTS AND EXPERT'S OPINION. <i>Eurasian Heart Journal</i> , 2021, , 92-102.	0.2	0
5	Retrospective analysis of electronic health records of patients with heart failure: the first Russian experience. <i>Russian Journal of Cardiology</i> , 2021, 26, 4502.	0.4	7
6	Approaches to Assessing the Quality of Observational Studies of Clinical Practice Based on the Big Data Analysis. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 584-593.	0.3	2
7	Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution. <i>Meditinskiy Sovet</i> , 2021, , 68-76.	0.1	0
8	Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. <i>Russian Journal of Cardiology</i> , 2021, 26, 4699.	0.4	1
9	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1491-1497.	0.2	6
10	Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion. <i>Russian Journal of Cardiology</i> , 2020, 25, 103-110.	0.4	5
11	CHANGING PERCEPTIONS OF TACTICS IN ACUTE MARKED INCREASE IN BLOOD PRESSURE IN THE ABSENCE OF DAMAGE TO TARGET ORGANS. <i>Å¼no-Rossijskij Å¼urnal TerapevtiÅ¼eskoj Praktiki</i> , 2020, 1, 33-37.	0.1	1
12	Results of studies promising to impact the management of cardiovascular diseases as presented at the virtual American College of Cardiology World Congress of Cardiology 2020. <i>Siberian Medical Journal</i> , 2020, 35, 174-179.	0.3	0
13	Vascular age concept: role in assessing risk and choosing therapy. <i>Meditinskiy Sovet</i> , 2020, , 51-57.	0.1	0
14	Latent opportunities for the prevention of ischemic stroke in patients with atherosclerosis-related diseases: additional analysis of randomized trials on rivaroxaban. <i>Russian Journal of Cardiology</i> , 2020, 25, 81-89.	0.4	0
15	Evidence-based approaches to comparing the effectiveness of modern cardiology interventions: trends, bias and prospects. <i>Russian Journal of Cardiology</i> , 2020, 25, 4037.	0.4	0
16	Anemia in Patients with Heart Failure: Current State of the Problem. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2019, 8, 68-73.	0.3	3
17	Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components. <i>Russian Journal of Cardiology</i> , 2019, , 112-121.	0.4	2